Cara Tenenbaum 2/19/26 Cara Tenenbaum 2/19/26

Sen. Cassidy’s FDA Report

Cara Tenenbaum 12/16/25 Cara Tenenbaum 12/16/25

Lyme Disease Conspiracy

Cara Tenenbaum 10/1/25 Cara Tenenbaum 10/1/25

Mifepristone Label

Cara Tenenbaum 3/25/25 Cara Tenenbaum 3/25/25

DTC Tests

Cara Tenenbaum 2/27/25 Cara Tenenbaum 2/27/25

Flu and Measles Vaccines…A Few Thoughts

Cara Tenenbaum 1/24/25 Cara Tenenbaum 1/24/25

Changes in FDA Guidances

Cara Tenenbaum 12/20/24 Cara Tenenbaum 12/20/24

House AI Task Force Report

Cara Tenenbaum 12/16/24 Cara Tenenbaum 12/16/24

Cell & Gene Therapy FAQ

Cara Tenenbaum 12/11/24 Cara Tenenbaum 12/11/24

Opinion Brief on Mifepristone

Cara Tenenbaum 12/3/24 Cara Tenenbaum 12/3/24

Predetermined Change Control Plans in AI Devices Submitted to FDA

Cara Tenenbaum 11/13/24 Cara Tenenbaum 11/13/24

Implantable Device Safety

Cara Tenenbaum 10/14/24 Cara Tenenbaum 10/14/24

Adderall Drug Shortage

Cara Tenenbaum 9/20/24 Cara Tenenbaum 9/20/24

Tubal Ligations

Cara Tenenbaum 4/3/24 Cara Tenenbaum 4/3/24

Senate RFI on LDTs

Cara Tenenbaum 4/2/24 Cara Tenenbaum 4/2/24

Artificial Intelligence and STIs

Cara Tenenbaum 2/23/24 Cara Tenenbaum 2/23/24

Senate White Paper on Privacy

Cara Tenenbaum 12/4/23 Cara Tenenbaum 12/4/23

Maternal Mortality and Digital Health

Cara Tenenbaum 9/29/23 Cara Tenenbaum 9/29/23

LDT Proposed Rule

Cara Tenenbaum 8/1/23 Cara Tenenbaum 8/1/23

Women’s Health in the Unified Agenda

Cara Tenenbaum 5/5/23 Cara Tenenbaum 5/5/23

Decentralized Clinical Trial Guidance